PDE10

PDE10 Related Products (54):

By Type:	Pan (25) Selective (10)
By Effects:	Inhibitors (52) Antagonists (2)

Cat. No.	Product Name	Effect	Purity

HY-50098

Mardepodect	Inhibitor	98.81%
Mardepodect is a potent, selective orally active, and brain-penetrant PDE10A inhibitor with an IC₅₀ of 0.37 nM, with >1000-fold selectivity over other PDEs.

HY-18252

Avanafil	Inhibitor	98.66%
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.

HY-111371

PF-05180999	Inhibitor	99.96%
PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC₅₀ of 1.6 nM.

HY-12472

Balipodect	Inhibitor	99.47%
Balipodect (TAK-063) is a selective, brain-penetrant and orally active PDE10A inhibitor with an IC₅₀ of 0.30 nM. Balipodect shows >15000-fold selectivity over other PDEs. Balipodect elevates striatal cAMP and cGMP levels in mice. Balipodect can be used for the study of schizophrenia_[1].

HY-14550

TP-10	Inhibitor	99.95%
TP-10 is a selective PDE10A inhibitor with an IC₅₀ value of 0.8 nM. TP-10 shows an antioxidant activity with IC₅₀s of 31.72 and 16.04 μg/ml for DPPH and CUPRAC, respectively. TP-10 can be used for the research of neuropathy.

HY-179639

PDE4-IN-30	Inhibitor
PDE4-IN-30 is a selective PDE4 inhibitor with an IC₅₀ of 2.7 nM for PED4D2, targeting PDE4 through halogen bonding and metal coordination. PDE4-IN-30 exhibits at least 67-fold selectivity for other PDE subfamilies. PDE4-IN-30 can be used for the research of idiopathic pulmonary fibrosis.

HY-181762

Multitarget AD-IN-6	Inhibitor
Multitarget AD-IN-6 (Compound 39) is a multi-target inhibitor, with an IC₅₀ of 15.54 μM against PDE4B, 15.15 μM against PDE7A, 8.39 μM against PDE3A, and a K_d of 37.7 μM against CHIT1. Multitarget AD-IN-6 acts as a TRPA1 antagonist, reduces the level of the NLRP3 inflammasome multiprotein complex to inhibit its activation, while inhibiting PDE4B, PDE7A and CHIT1, and decreasing the phosphorylation of NF-κB. Multitarget AD-IN-6 improves the pathology of elastase-induced emphysema in mice. Multitarget AD-IN-6 is applicable for the research of chronic obstructive pulmonary disease.

HY-120291

ASP9436	Inhibitor
ASP9436 is an orally active and blood-brain barrier permeable PDE10A inhibitor with an IC₅₀ of 8 nM against human PDE10A. ASP9436 attenuates locomotor activity in mouse hyperactivity models and ameliorates visual recognition memory impairment in neonatal mice. ASP9436 is applicable to research related to schizophrenia.

HY-153093

Elpipodect	Inhibitor	98.95%
Elpipodect (MK-8189) is an orally active and selective PDE10A inhibitor with a K_i value of 29 pM. Elpipodect can be used in research of schizophrenia.

HY-108618

BC11-38	Inhibitor	99.42%
BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC₅₀s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells.

HY-100530C

Sp-cAMPS sodium salt	Inhibitor	99.45%
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-177295

Naperiglipron	Inhibitor	99.43%
Naperiglipron (LY3549492) is an orally active Glucagon-like peptide 1 receptor (GLP-1R) agonist with an EC₅₀ of 1.14 nM for hGLP-1R. Naperiglipron significantly decreases the level of blood glucose in GLP-1R knock-in mouse models. Naperiglipron inhibits PDE10A1 enzyme activity (IC₅₀: 7.43 μM) with a weak hERG inhibitory activity. Naperiglipron can be used for type II diabetes mellitus (T2DM) and obesity research.

HY-50098A

Mardepodect hydrochloride	Inhibitor	99.94%
Mardepodect hydrochloride (PF-2545920 hydrochloride) is a potent, orally active and selective PDE10A inhibitor with an IC₅₀ of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect hydrochloride can cross the blood-brain barrier.

HY-W003486

5,7-Dichloropyrazolo[1,5-a]pyrimidine	Inhibitor	99.69%
5,7-Dichloropyrazolo[1,5-a]pyrimidine is a PDE10A inhibitor with a K_i of 24 μM. 5,7-Dichloropyrazolo[1,5-a]pyrimidine serves as a key intermediate in the synthesis of 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives (HIV-1 non-nucleoside reverse transcriptase inhibitors). 5,7-Dichloropyrazolo[1,5-a]pyrimidine can be used for the research of schizophrenia.

HY-155830

Morcamilast	Inhibitor	98.92%
Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC₅₀s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056)-induced release of TNF-α, IL-12/23p40, IL-23, and IL-17A in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases.

HY-135848

N-Methylbenzamide	Inhibitor	99.93%
N-Methylbenzamide is a potent phosphodiesterase 10A (PDE10A) inhibitor. N-Methylbenzamide has anti-cancer activity.

HY-A0165

Tofisopam	Inhibitor	99.46%
Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent. Tofisopam can inhibit phosphodiesterase PDE isoenzyme activity, withIC₅₀ values of 2.11 μM, 1.98 μM, 0.42 μM, and 0.92 μM for PDE-2A3, PDE-3A, PDE-4A1, and PDE-10A1, respectively. Tofisopam can be used for the study of anxiety.

HY-124775

(S)-C33	Inhibitor	99.46%
(S)-C33 is a potent and selective PDE9 (phosphodiesterase-9) inhibitor, with an IC₅₀ of 11 nM. (S)-C33 can be used for central nervous system diseases and diabetes research.

HY-117604

THPP-1	Inhibitor	98.75%
THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with K_i values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species.

HY-100530B

Sp-cAMPS	Inhibitor
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

Name
Email *

	Sorry, but the email address you supplied was invalid.